WuXi XDC Launches Takeover Offer for BioDlink International, Forecasts Rise in 2025 Profit

MT Newswires Live

01/15

WuXi XDC (HKG:2268) made an offer to acquire BioDlink International (HKG:1875) for HK$4 per share in cash, according to a joint statement Wednesday.

Shares of the contract research, development and manufacturing organization fell nearly 3% in morning trade Thursday, while BioDlink jumped nearly 69%.

The offer represents a maximum consideration of HK$2.79 billion for the business. WuXi XDC plans to retain BioDlink's Hong Kong listing after the acquisition.

BioDlink said it had formed an independent board committee to advise shareholders on the offer.

Meanwhile, WuXi XDC said it expects its net profit for 2025 to rise by at least 38% year-on-year. The firm posted 1.07 billion yuan in profit attributable to owners for 2024.

Revenue for the year is expected to rise at least 45% when compared to the 4.05 billion yuan posted in 2024.

The company expects to post its financial results by March 23.

WuXi XDC is controlled by WuXi Biologics (HKG:2269).

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2603622754"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603622754\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603622754?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-15 11:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603622754","market":"nz","top_or_hot":-1,"title":"WuXi XDC Launches Takeover Offer for BioDlink International, Forecasts Rise in 2025 Profit","media":"MT Newswires Live","content":"<html><body><p> WuXi XDC (HKG:2268) made an offer to acquire BioDlink International (HKG:1875) for HK$4 per share in cash, according to a joint statement Wednesday.</p><p>Shares of the contract research, development and manufacturing organization fell nearly 3% in morning trade Thursday, while BioDlink jumped nearly 69%.</p><p>The offer represents a maximum consideration of HK$2.79 billion for the business. WuXi XDC plans to retain BioDlink's Hong Kong listing after the acquisition.</p><p>BioDlink said it had formed an independent board committee to advise shareholders on the offer.</p><p>Meanwhile, WuXi XDC said it expects its net profit for 2025 to rise by at least 38% year-on-year. The firm posted 1.07 billion yuan in profit attributable to owners for 2024.</p><p>Revenue for the year is expected to rise at least 45% when compared to the 4.05 billion yuan posted in 2024.</p><p>The company expects to post its financial results by March 23.</p><p>WuXi XDC is controlled by WuXi Biologics (HKG:2269).</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>WuXi XDC Launches Takeover Offer for BioDlink International, Forecasts Rise in 2025 Profit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWuXi XDC Launches Takeover Offer for BioDlink International, Forecasts Rise in 2025 Profit\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-01-15 11:21</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> WuXi XDC (HKG:2268) made an offer to acquire BioDlink International (HKG:1875) for HK$4 per share in cash, according to a joint statement Wednesday.</p><p>Shares of the contract research, development and manufacturing organization fell nearly 3% in morning trade Thursday, while BioDlink jumped nearly 69%.</p><p>The offer represents a maximum consideration of HK$2.79 billion for the business. WuXi XDC plans to retain BioDlink's Hong Kong listing after the acquisition.</p><p>BioDlink said it had formed an independent board committee to advise shareholders on the offer.</p><p>Meanwhile, WuXi XDC said it expects its net profit for 2025 to rise by at least 38% year-on-year. The firm posted 1.07 billion yuan in profit attributable to owners for 2024.</p><p>Revenue for the year is expected to rise at least 45% when compared to the 4.05 billion yuan posted in 2024.</p><p>The company expects to post its financial results by March 23.</p><p>WuXi XDC is controlled by WuXi Biologics (HKG:2269).</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0456827905.SGD","symbol_name":"JPMorgan Funds - China A (acc) SGD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2603622754","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603622754","pubTimestamp":1768447295,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"WuXi XDC (HKG:2268) made an offer to acquire BioDlink International (HKG:1875) for HK$4 per share in cash, according to a joint statement Wednesday.Shares of the contract research, development and man","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","BK1161":"生物科技","BK1610":"ETF&股票定投概念","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","02268":"药明合联","LU0052750758.USD":"富兰克林中国基金A Acc","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","BK1576":"医药外包概念","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","02269":"药明生物","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU3063872942.SGD":"FULLERTON LUX FUNDS ASIA EQUITIES \"I\" (SGD) ACC","BK1574":"生物医药B类股","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","LU0039217434.USD":"HSBC GIF CHINESE EQUITY \"AD\" INC","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","BK1521":"挪威政府全球养老基金持仓","LU0140636845.USD":"施罗德大中华区股票A Acc","01875":"东曜药业-B","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","LU0823426480.USD":"法巴中国股票经典Dis","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0823426308.USD":"法巴中国股票基金","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","BK1589":"北水核心资产","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC","LU0359201612.USD":"贝莱德中国基金A2","SG9999014674.SGD":"Nikko AM All China Equity A SGD","SG9999002562.SGD":"LionGlobal Asia Pacific SGD","BK1141":"生命科学工具和服务","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","LU1688375341.USD":"贝莱德中国灵活股票基金","LU0051755006.USD":"摩根大通中国A (dist)","SG9999002463.SGD":"LionGlobal China Growth SGD","LU1720050803.USD":"安联全方位中国股票基金"},"translate_title":"无锡XDC向BioDlink International发起收购要约，预计2025年利润将增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01875":1,"02269":1,"02268":1},"content_text":"WuXi XDC (HKG:2268) made an offer to acquire BioDlink International (HKG:1875) for HK$4 per share in cash, according to a joint statement Wednesday.Shares of the contract research, development and manufacturing organization fell nearly 3% in morning trade Thursday, while BioDlink jumped nearly 69%.The offer represents a maximum consideration of HK$2.79 billion for the business. WuXi XDC plans to retain BioDlink's Hong Kong listing after the acquisition.BioDlink said it had formed an independent board committee to advise shareholders on the offer.Meanwhile, WuXi XDC said it expects its net profit for 2025 to rise by at least 38% year-on-year. The firm posted 1.07 billion yuan in profit attributable to owners for 2024.Revenue for the year is expected to rise at least 45% when compared to the 4.05 billion yuan posted in 2024.The company expects to post its financial results by March 23.WuXi XDC is controlled by WuXi Biologics (HKG:2269).","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}